J. Weiss

发表

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.

M. Hallek, S. Stilgenbauer, S. Böttcher, 2020, Blood.

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms

L. Tsoi, T. Tejasvi, C. Lyssiotis, 2022, Blood Cancer Journal.

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

William Pao, Michael Hölzel, Martin Peifer, 2011, Clinical Cancer Research.

Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients

Kenneth D. Doig, S. Fox, A. Dobrovic, 2015, British Journal of Cancer.

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Laura Tolosi, Michael Peyton, Thomas Zander, 2009, The Journal of clinical investigation.

Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine

Thomas John, Vivek Rathi, Alexander Dobrovic, 2014, Oncotarget.

The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells

Jürgen Hescheler, Holm Zaehres, J. Hescheler, 2008, Biological chemistry.

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.

A. Rosenwald, W. Klapper, A. Hagenbeek, 2021, Med.

In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability

Roman K. Thomas, M. Peifer, M. Sos, 2019, bioRxiv.

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

Viktor Achter, Ulrich Lang, Martin Peifer, 2018, Nature Communications.

Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease

A. Rosenwald, W. Klapper, A. Hagenbeek, 2021, medRxiv.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Martin Peifer, Daniel Rauh, Lars Ruddigkeit, 2010, Cancer research.

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

William Pao, Thomas Zander, Martin Peifer, 2009, Proceedings of the National Academy of Sciences.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

M. Meyerson, C. Mermel, B. Weir, 2009, Cancer research.

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Alexander Dobrovic, A. Dobrovic, A. Behren, 2015, Scientific Reports.

Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

Martin Peifer, Daniel Rauh, Jörg Rahnenführer, 2010, PloS one.

The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients

M. Hallek, K. Kreuzer, M. Schlaak, 2020, Scientific Reports.

Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18.

Hanmin Lee, Aaron B Caughey, Dick Oepkes, 2012, American journal of obstetrics and gynecology.

Epigenetic abnormalities of the mannose-6-phosphate/IGF2 receptor gene are uncommon in human overgrowth syndromes

C. Gicquel, V. Gaston, Y. Le Bouc, 2004, Journal of Medical Genetics.

Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations

S. Fox, H. Do, A. Dobrovic, 2014, British Journal of Cancer.

Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.

K. Hekmat, A. Quaas, J. Wolf, 2020, Lung cancer.

Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax.

M. Hallek, S. Stilgenbauer, M. Ritgen, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)

M. Peifer, M. Hallek, J. Weiss, 2019, Haematologica.

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

M. Peifer, M. Hallek, O. Merkel, 2018, Nature Communications.

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence

T. Zander, A. Quaas, M. Hallek, 2018, Scientific Reports.

Outlier expression of isoforms by targeted or total RNA sequencing identifies clinically significant genomic variants in hematolymphoid tumors.

Annette S. Kim, M. Harris, L. Silverman, 2023, The Journal of molecular diagnostics : JMD.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer

M. Hellmich, M. Mallmann, S. Merkelbach-Bruse, 2023, Journal of Cancer Research and Clinical Oncology.